Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPR | P35270 | 3/20 | 0.43 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.42 |
| ▸ | NAMPT | P43490 | 5/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | FNTA | P49354 | 1/20 | 0.35 |
| ▸ | FNTB | P49356 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 1/20 | 0.35 |
| ▸ | OGA | O60502 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12821125 | 0.85 | CREBBP (0.50) | SPRENPP2NAMPTBRD4CREBBP | |
| SCHEMBL13373596 | 0.82 | RIPK1 (0.48) | SPRENPP2NAMPTNR1H2PDK2 | |
| SCHEMBL13373469 | 0.81 | SPR (0.43) | SPRENPP2NAMPTBRD4CREBBP | |
| SCHEMBL13373417 | 0.80 | NOTUM (0.50) | SPRNAMPTBRD4CREBBP | |
| SCHEMBL18334871 | 0.79 | SPR (0.40) | SPRENPP2NAMPTNR1H2PDK2 | |
| SCHEMBL1018783 | 0.78 | NR1H2 (0.58) | SPRNAMPTNR1H2 | |
| SCHEMBL15156435 | 0.78 | NAMPT (0.47) | SPRENPP2NAMPTNR1H2PDK2 | |
| SCHEMBL5119961 | 0.77 | NAMPT (0.46) | SPRENPP2NAMPTNR1H2PDK2 | |
| SCHEMBL6110578 | 0.77 | LMNA (0.47) | SPRENPP2NAMPTNR1H2GRM5 | |
| SCHEMBL13373502 | 0.76 | SPR (0.45) | SPRENPP2NAMPTNR1H2OGA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149683-A1 | SUBSTITUTED AMINOPIPERIDINES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OF DIABETES | MERCK SHARP & DOHME LLC | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149683-A1 | SUBSTITUTED AMINOPIPERIDINES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OF DIABETES | DPP4, DPP3, DPP7 | SPR 320/4885ENPP2 249/4885NAMPT 1272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.